TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00314132

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax-JE, Japanese Encephalitis vaccine
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: 0.5 mL, Subcutaneous
Study: NCT03602794

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECs Block
Description: Regional Anaesthesia Technique ie Pectoralis Nerve Block under ultrasound guidance

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Local infiltration
Description: LIA will be performed by surgeon during the operation. The upper skin flap will be raised in the standard manner for mastectomy. The lateral border of the major pectoralis muscle will then be visualised. A volume of 10 ml ropivacaine 0.5% will be delivered between the inter-fascial planes of the pectoral muscles. The lower skin flap will then be raised in the standard manner for mastectomy and the breast is raised off the pectoralis muscle exposing the serratus anterior muscle. A volume of 20 ml ropivacaine 0.5% will be delivered between the muscle planes of the serratus anterior and pectoralis minor muscles.
Study: NCT03972397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intercostal Nerve Cryoablation
Description: Patients will receive intraoperative intercostal nerve cryoablation using CryoICE® CRYO2 cryoablation probes (AtriCure, Inc) to intercostal spaces 4th to 10th in thoracoabdominal aortic repairs and 4th to 8th in descending thoracic aortic repair cases prior to wound closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposomal injectable suspension
Description: Patients from both groups will receive the same volume of diluted Exparel®, which will be given in four 20ml syringes using 22-gauge needles (266mg of liposomal bupivacaine, equivalent of one 1.3% 20ml vial of EXPAREL, diluted in 50ml of preservative-free normal (0.9%) sterile saline for a total volume of 70ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine liposomal injectable suspension
Description: Patients from both groups will receive the same volume of diluted Exparel®, which will be given in four 20ml syringes using 22-gauge needles (266mg of liposomal bupivacaine, equivalent of one 1.3% 20ml vial of EXPAREL, diluted in 50ml of preservative-free normal (0.9%) sterile saline for a total volume of 70ml).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Description: Patients will have access to the standard PCA (Patient-Controlled Analgesia) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10-minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled analgesia (PCA)
Description: Patients will have access to the standard PCA (Patient-Controlled Analgesia) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10-minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs.
Study: NCT03068221

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: anaerobic exercise
Description: assessing anaerobic exercise status

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: anaerobic exercise
Description: assessing anaerobic exercise status
Study: NCT02440737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive publication, When Someone You Love is Being Treated for Cancer, a preliminary individualized Survivorship Care Plan (SCP), a final individualized SCP, and the REACH for Survivorship handbook.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-Up Care
Description: Complete Survivorship Care Planning session at end of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychosocial Assessment and Care
Description: Undergo the NEST intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02154477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal insulin
Description: insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal insulin
Description: insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo (intranasal saline)
Description: saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo (intranasal saline)
Description: saline
Study: NCT05008263

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver elastography (2D-SWE)
Description: All patients were referred for 2D-SWE liver elastography and liver liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver scintigraphy with 99mTc-mebrofenin
Description: All patients were referred for 2D-SWE liver elastography and liver liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy.
Study: NCT02899819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: meconium
Description: The meconium will be sampled in the first 2 days of life
Study: NCT01037413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXC 001
Description: Multiple intradermal injections of EXC 001 and placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple intradermal injections of EXC 001 and placebo
Study: NCT02934542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoLap system
Study: NCT04550286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Use Reduction in Academic Context
Description: Students will be given general advice on how to organize their exam preparation environment and behavior to improve their overall learning performance (e.g., organization of materials for exam preparation, pauses during exam preparation). This refers to the behavior change techniques (BCT 4.1, instructions on how to perform the behavior; Michie et al.; 2013).~In the next step, participants in the intervention group complete planning sheets. Each student has to develop up to three action plans (BCT 1.4) including when, where, and for how long the smartphone will be put away during the daily exam preparation period (cf. Radtke et al., 2018). In addition, each participant should try to anticipate possible barriers to engaging in the planned behavior and plan what he or she could do to overcome these possible barriers (i.e., coping planning; BCT 1.2; Michie et al., 2013).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Students will be given general advice on how to organize their exam preparation environment and behavior to improve their overall learning performance (e.g., organization of materials for exam preparation, pauses during exam preparation).
Study: NCT01218295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spirotiger®
Description: training session :10 minutes twice a day X 4 weeks
Study: NCT03739697

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spontaneous breathing
Description: spontaneous breathing during induction of anesthesia in infants
Study: NCT01579110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levamisole
Description: Levamisole 2.5mg/kg(every other day) over six months.~Prednisone 1mg/kg for two weeks and then tapered off dosage over two months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 1mg/kg for two weeks and then tapered off dosage over two months.
Study: NCT02315053

Intervention type: OTHER
Group type: OTHER
Intervention: Low dose FDG PET/CT 5 x.
Description: Multiple FDG PET/CT studies will be added to the normal diagnostic procedures as a part of this study, with the number of scans depending on the study stage, to a maximum of 6 per patient.
Study: NCT02243761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBT Based Skills Groups for Families
Description: 12 weeks of Dialectical Behaviour Therapy skills training group for families (90-minute once-weekly sessions)
Study: NCT02106637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: drug will be initiated during hospitalization and continued for 12 weeks following discharge

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04326153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab Injection
Description: Preoperative:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of two cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total~Postoperative:~Patients began to receive postoperative adjuvant treatment within 21-60 days after the operation. Specific medication plan:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of 8 cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total.
Study: NCT00225277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Up to 45 mg pioglitazone (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Up to 4 mg of glimepiride (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
Study: NCT02569320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDAC Inhibitor AR-42
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study: NCT01448525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost ophthalmic solution 0.03%
Description: One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bimatoprost vehicle solution
Description: One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
Study: NCT05342116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nestle Preload
Description: 1 sachet of Preload (50g) diluted with 400ml of water, to be consumed 2 to 4 hours prior to the endoscopy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: 400ml of water to be consumed 2 to 4 hours prior to the endoscopy.
Study: NCT00981825

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Whole mouth brushing for 7 days
Study: NCT01469975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTSA101-DTPA-90Y level 1
Description: Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 370MBq of 90Y will be administered IV as a single injection on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTSA101-DTPA-90Y level 2
Description: Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 1110 MBq of 90Y will be administered IV as a single injection on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTSA101-DTPA-90Y level 3
Description: Part 2 of the study 3 mg of OTSA101-DTPA radiolabelled with 2220 MBq of 90Y will be administered IV as a single injection on Day 0.~This third dose level evaluation will be based on safety and preliminary efficacy data.
Study: NCT01448603

Intervention type: BIOLOGICAL
Intervention: Placebo
Description: No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.

Intervention type: BIOLOGICAL
Intervention: ToleroMune Ragweed
Description: No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.

Intervention type: BIOLOGICAL
Intervention: ToleroMune Ragweed
Description: No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.

Intervention type: BIOLOGICAL
Intervention: ToleroMune Ragweed
Description: No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.

Intervention type: BIOLOGICAL
Intervention: ToleroMune Ragweed
Description: No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
Study: NCT02046798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: oral
Study: NCT02923609

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell Therapy
Description: Electro-anatomical mapping will be performed using the Biosense NOGA system (Biosense-Webster, Diamond Bar, California). Local diastolic function will be assessed by a novel algorhithm that allows for the measuring local ventricular relaxation times at each of the sampling points. Target areas for cell delivery will be defined as the myocardial segments with the evidence of local diastolic dysfunction and myocardial hibernation. Transendocardial delivery of cell suspension in the SC Group will be performed with MyoStar® (Biosense Webster) injection catheter. Each patient will receive 20 injections of 0.3 mL of stem cell suspension.
Study: NCT03411928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tracheolator
Description: 'Tracheolator' non-occlusive tracheal dilation balloon manufactured by Disa Life Sciences, Cape Town, South Africa.
Study: NCT01836991

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Study: NCT01803776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle counseling
Description: The physical activity and dietary intervention is based on the Finnish physical activity and dietary recommendations. The children and their parents in the intervention group undergo individualized and family-based physical activity and dietary intervention between the baseline and 2-year follow-up examinations. The children and their parents meet a physical activity specialist and a nutritionist who give detailed and individualized instructions on health promoting physical activity and diet at months 0, 1.5, 3, 6, 12, and 18 with a specific topic at each visit. Between the 2-year follow-up and 8-year follow-up examinations, the intervention continues with yearly physical activity and dietary counseling sessions. The children in the intervention group, particularly those who do not attend organized sports or exercise, will also be encouraged to participate in after-school exercise clubs organized by trained exercise instructors of the study.
Study: NCT02331849

Intervention type: DEVICE
Group type: OTHER
Intervention: High resolution manometry (HRM)
Description: High resolution manometry of the esophagus
Study: NCT00899704

Intervention type: GENETIC
Intervention: microarray analysis

Intervention type: GENETIC
Intervention: allele-specific oligonucleotide real-time quantitative polymerase chain reaction

Intervention type: OTHER
Intervention: diagnostic laboratory biomarker analysis
Study: NCT03479944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FLACS
Description: Femtosecond laser assisted cataract surgery consisting of LenSx® and Centurion® combination

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual conventional surgery
Description: Removal of cataractous lens by phacoemulsification

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CENTURION® Vision System
Description: Phacoemulsification aspiration platform for use during cataract surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CENTURION® Vision System
Description: Phacoemulsification aspiration platform for use during cataract surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LenSx®
Description: Femtosecond laser system used for continuous curvilinear capsulorhexis (CCC) and lens fragmentation during cataract surgery
Study: NCT05631782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Shenkang decoction
Description: Given Shenkang decoction on the basis of the above treatment. Shenkang decoction prescription: 15 g of semen cuscutae, herba epimedii and pericarpium arecae. 20 g of Eucommia ulmoides Oliv., radix astragali, codonopsis pilosula, salvia miltiorrhiza, tuckahoe, atractylodes macrocephala, Chinese yam, honeysuckle, polyporus umbellatus and dandelion. 15 g of safflower. 12 g of processed Fuzi. 10 g of Radix phytolaccae and sage. Golden cherry son 20 g and puzzle kernel 15 g were added to patients with frequent proteinuria and nocturia took. Yellow cypress 15 g was added to patients with damp-heat in lower-Jiao. The decoction pieces were purchased from the Traditional Chinese Medicine and Pharmacy Department of the First People's Hospital of Zunyi City. They were decocted by computer automatic decocting machine (model) and divided into 150 mL / bag, taken orally, once in the morning, noon and evening, 3 times / day, 1 bag / time, one pair a day. Treatment lasted for 10 - 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenkang decoction
Description: Given Shenkang decoction on the basis of the above treatment. Shenkang decoction prescription: 15 g of semen cuscutae, herba epimedii and pericarpium arecae. 20 g of Eucommia ulmoides Oliv., radix astragali, codonopsis pilosula, salvia miltiorrhiza, tuckahoe, atractylodes macrocephala, Chinese yam, honeysuckle, polyporus umbellatus and dandelion. 15 g of safflower. 12 g of processed Fuzi. 10 g of Radix phytolaccae and sage. Golden cherry son 20 g and puzzle kernel 15 g were added to patients with frequent proteinuria and nocturia took. Yellow cypress 15 g was added to patients with damp-heat in lower-Jiao. The decoction pieces were purchased from the Traditional Chinese Medicine and Pharmacy Department of the First People's Hospital of Zunyi City. They were decocted by computer automatic decocting machine (model) and divided into 150 mL / bag, taken orally, once in the morning, noon and evening, 3 times / day, 1 bag / time, one pair a day. Treatment lasted for 10 - 14 days.
Study: NCT01669785

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group C
Description: Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group A
Description: Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group B
Description: Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
Study: NCT03423966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone Pedometer App
Description: Installation of the free pedometer app and explanation to participants to target 10000 steps per day. The intent is not the accuracy of the pedometer but the motivation especially to a community yet to harness the full potentials of the mobile phone technology
Study: NCT02466607

Intervention type: DEVICE
Group type: OTHER
Intervention: RETeval color flicker ERG
Description: Flicker ERGs obtained to 56 CIE 1931 (created by the International Commission on Illumination (CIE) in 1931) colors series. White flash of 0,33, 0,33 was used for comparison.

Intervention type: DEVICE
Group type: OTHER
Intervention: RETeval dilated versus un-dilated flicker ERG
Description: Two series of white flashes: 3,0 cd/m2/sec and Trolands equivalent assuming 3,7 mm pupil size, delivered at 3 min interval over 30 min.

Intervention type: OTHER
Group type: OTHER
Intervention: pupil dilation
Description: Pupil will be dilated using Proparacaine 0.5% and Tropicamide 0.5%
Study: NCT03750409

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helmet
Description: The portable device covers the head and weighs about 3.5 lb., and is made of light-weight, durable plastic, it is placed on the head with eye panels facing forward. Elastic straps holding the arrays together easily expand to conform to each subjects' head. Patients may notice slight warming of scalp after usage. This warming effect is similar to wearing a regular motorcycle helmet for a similar duration.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Helmet
Description: The portable device covers the head and weighs about 3.5 lb., and is made of light-weight, durable plastic, it is placed on the head with eye panels facing forward. Elastic straps holding the arrays together easily expand to conform to each subjects' head. Patients may notice slight warming of scalp after usage. This warming effect is similar to wearing a regular motorcycle helmet for a similar duration.
Study: NCT01726621

Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic MiniMed 620G or 640G Insulin Pump
Description: Subjects to use the Medtronic MiniMed 620G or 640G Insulin Pump and Guardian Link transmitter to manage their diabetes for 4 - 6 weeks.
Study: NCT00552032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate nasal spray
Description: Mometasone Furoate nasal spray 1 puff (50 mcg) per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray 1 puff per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
Study: NCT03299894

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: systematic calculation of qSOFA
Description: calculation of qSOFA for each patient
Study: NCT03595267

Intervention type: OTHER
Intervention: Point-of-care screening
Description: After consent is obtained, a registered nurse will administer a demographic questionnaire, collecting the participant's personal health number, age, gender, date of birth, and name of community. Physical data including height, weight, and blood pressure will also be collected. A blood sample and a urine sample will be taken, with point-of-care testing being performed during the screening appointment to allow for results of the testing to be received and discussed with each patient at the time of the appointment. After screening, to ensure a closed loop system of care, patients at the highest risk of kidney failure will be referred to a nephrologist, while those at lower risk will be referred to their primary care provider with specific treatment and re-testing recommendations.